Septerna Inc (SEPN)

NASDAQ • Healthcare

$36.75

-$0.04 (-0.1%)

Market closed

Last close at September 4, 2026 at 20:00 UTC

Day Range$36.57 - $37.59

Avg. Volume (3M)437.7K

Market Cap$1.6B

52 Week Range

$13.67$51.1

Next EarningsIn 66 daysNov 9, 2026

Metrics Over Time

Where the Money Goes

Q2 2026

Revenueeverything earned$26.7M100%

Gross Profitminus cost of goods$26.7M100%

In plain terms: out of every $100 in revenue, Septerna Inc currently loses $49.

Fundamentals & Financials

Revenue (TTM)

$98.8M

Net Income (TTM)

-$24.2M

EPS (TTM)

-$0.54

ROA (TTM)

-4.28%

Current Ratio

4.99

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

-1020.0%Q3 2025-$0.56

-147.4%Q4 2025-$0.09

-4.3%Q1 2026-$0.24

+62.7%Q2 2026-$0.19

+31.9%Q3 2026-$0.29

Nov 9

in 66 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Septerna Inc

Septerna Inc, listed on NASDAQ as SEPN, is a biotechnology company that discovers and develops oral small molecule medicines targeting G protein-coupled receptors. Its work centers on endocrinology, immunology and inflammation, and metabolic disease, and it generated $46.0 million of revenue in FY2025.

Name

Septerna Inc

CEO

Jeffrey T. Finer

Website

septerna.com

Industry

Healthcare

Year Founded

2019

Employees

123

Today's Snapshot

AI-generated

SEPN ended the day slightly lower at 36.75, while its sector was weaker. Volume was about two-thirds of its usual level.

Trading Volume

Below 10d avg (304.8K)

188.6K

vs S&P 500 Today

Moderate Outperformance

+0.28%

Updated: September 4, 2026 at 20:03 UTC

Technical Indicators

3 Buy1 Neutral4 Sell

SEPN shows a conflicted technical picture with limited trend strength—ADX under 19—while momentum measures, MACD and CCI are tilted negative and RSI sits below neutral. Short- and medium-term averages sit above the current price, yet 100- and 200-day averages remain well below, so longer-term support coexists with near-term pressure. ATR is elevated around 5.5% and OBV reads as negative, while the pivot is close to the market. These mixed signals result in a neutral technical stance. Technical takeaway: Overall view is Neutral.

All signals